News

UrgentRx introduces 10-count multipack boxes

BY Michael Johnsen

DENVER — UrgentRx on Monday announced the expansion of its product line to include UrgentRx Fast Powders 10-count multipack boxes of its single-dose packets for a variety of common ailments. UrgentRx 10-count boxes are now available nationwide for Headache Relief to Go, Heartburn Relief to Go, Upset Stomach Relief to Go, Ache & Pain Relief to Go, Allergy Attack Relief to Go and Critical Care Aspirin. 
 
“We are constantly pushing ourselves to listen to our customers and develop innovative products based on their feedback. As a result, we are challenging the traditional perceptions of symptom relief and how to best address it,” stated Jordan Eisenberg, CEO UrgentRx. “UrgentRx Fast Powders’ ease and convenience has really resonated with busy, on-the-go users who don’t have the time to slow down for a headache or annoying aches and pains. Our new multipack offerings – and an even smaller packet size – provide a better solution than ever before to help them feel better fast while on the go.”
 
UrgentRx multipack offerings include 10 single-dose packages — now in an even smaller on-the-go stick pack — that can easily be slipped into a pocket, wallet, handbag, gym bag or backpack, the company stated. 
 
UrgentRx Fast Powders 10-count boxes retail for a suggested $6.99 and are available in the OTC set at food, drug and mass retailers nationwide. UrgentRx single-dose offerings, available at the front checkout of more than 20,000 food, drug and mass retailers nationwide, retail for $1.39. National retailer partners include Walgreens and CVS in addition to major regional retailers including HEB, Meijer and Wakefern.
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
News

CDC: More than half of a projected 150 million-plus flu shots have been distributed to date

BY Michael Johnsen

ATLANTA — As of mid-August, seven influenza vaccine manufacturers projected that as many as 151 million to 159 million doses of influenza vaccine will be available for use in the United States during the 2014-2015 influenza season, the Centers for Disease Control and Prevention noted on a web page updated Friday.
 
"Some companies have communicated information to their customers about delays in shipments that had originally been anticipated for August and September," the agency reported. "Despite these early season shipping delays, however, manufacturers anticipate the majority of their flu vaccine distribution will occur by the end of October. While this is slightly later than vaccine was shipped last year, it is not an unusual pattern for seasonal flu vaccine distribution overall."
 
Since Sept. 26, 87.9 million doses had been distributed.
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
News

CRN defends structure function claims in brief filed to U.S. Department of Justice

BY Michael Johnsen

WASHINGTON — The Council for Responsible Nutrition on Monday urged the U.S. District Court in New Jersey to hold the Federal Trade Commission to the flexible “competent and reliable scientific evidence” standard for review of dietary supplement advertising. In a brief filed Friday, CRN addressed a motion by the U.S. Department of Justice on behalf of the FTC, with respect to Bayer Healthcare’s advertising claims for its probiotic supplement Phillips’ Colon Health. 

 
CRN’s brief argues that by requiring multiple randomized, placebo-controlled, and double-blind human clinical trials using the specific product for which the claims are made and are performed in the population at which the claims are directed, the FTC is invoking “a rigid standard for the substantiation of non-disease claims made about dietary supplements that is a significant departure from the current well-established, consistent and flexible federal regulatory regime upon which the entire dietary supplement industry has long relied.”
 
The brief further outlined the negative consequences that would come as a result of the government overreaching its authority, saying the change “would significantly impair the flow of truthful, valuable and scientifically sound information about dietary supplement products and limit consumers’ ability to make fully-informed nutrition-related decisions.” The standard of substantiation proposed by the FTC would impose drug-like requirements on dietary supplements that go far beyond what Congress intended and would effectively apply the medically-based, treatment-focused regulatory framework for drugs to dietary supplements. The evaluation of structure-function claims would essentially be treated the same as disease claims, which is contrary to the intent of the law.
 
“We are concerned that, if successful, FTC’s attempt to impose this legally-unprecedented review of advertising claims for supplements could eliminate many structure-function claims and disregard a wealth of rigorous scientific data that does not meet the narrow drug-like requirements," said Steve Mister, CRN president and CEO. "It would chill the First Amendment rights of manufacturers, marketers and consumers to communicate and to receive truthful information about the health benefits of these products.” 
 
 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?